DaBlaCa-16: Retrosigmoid Versus Conventional Ileal Conduit in Robot-assisted Radical Cystectomy, the MOSAIC Randomized Controlled Trial-Feasibility and 90-day Postoperative Complications.

"

 Financial disclosures: Simone Buchardt Brandt certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Financial disclosures:"

"

Financial disclosures: Simone Buchardt Brandt certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. 

Funding/Support and role of the sponsor: The study was supported by Christian Larsen and Judge Ellen Larsens Fond, and Louis-Hansens Fond."

"This open-label, randomized controlled trial was conducted from May 2020 until August 2022. In total, 303 patients were enrolled from all five centers performing RC in Denmark. The protocol was approved by the Central Denmark Region Committee on Health Research Ethics (1-10-72-72-20), and was registered on clinicaltrials.gov (NCT04391790) and on the internal list of research projects in the Central Denmark Region approved by the Danish Data Protection Agency. Informed written consent was obtained before randomization."